Stocks & Investing
Stocks and Investing
Stocks and Investing
Mon, November 14, 2022
[ Mon, Nov 14th 2022
] - WOPRAI
[ Mon, Nov 14th 2022
] - WOPRAI
[ Mon, Nov 14th 2022
] - WOPRAI
[ Mon, Nov 14th 2022
] - WOPRAI
[ Mon, Nov 14th 2022
] - WOPRAI
[ Mon, Nov 14th 2022
] - WOPRAI
[ Mon, Nov 14th 2022
] - WOPRAI
[ Mon, Nov 14th 2022
] - WOPRAI
[ Mon, Nov 14th 2022
] - WOPRAI
[ Mon, Nov 14th 2022
] - WOPRAI
[ Mon, Nov 14th 2022
] - WOPRAI
[ Mon, Nov 14th 2022
] - WOPRAI
[ Mon, Nov 14th 2022
] - WOPRAI
[ Mon, Nov 14th 2022
] - WOPRAI
[ Mon, Nov 14th 2022
] - WOPRAI
[ Mon, Nov 14th 2022
] - WOPRAI
[ Mon, Nov 14th 2022
] - WOPRAI
[ Mon, Nov 14th 2022
] - WOPRAI
[ Mon, Nov 14th 2022
] - WOPRAI
[ Mon, Nov 14th 2022
] - WOPRAI
[ Mon, Nov 14th 2022
] - WOPRAI
[ Mon, Nov 14th 2022
] - WOPRAI
[ Mon, Nov 14th 2022
] - WOPRAI
[ Mon, Nov 14th 2022
] - WOPRAI
[ Mon, Nov 14th 2022
] - WOPRAI
[ Mon, Nov 14th 2022
] - WOPRAI
[ Mon, Nov 14th 2022
] - WOPRAI
[ Mon, Nov 14th 2022
] - WOPRAI
Matthew Biegler Maintained (VOR) at Buy with Decreased Target to $18 on, Nov 14th, 2022
Matthew Biegler of Oppenheimer, Maintained "Vor Biopharma Inc." (VOR) at Buy with Decreased Target from $27 to $18 on, Nov 14th, 2022.
Matthew has made no other calls on VOR in the last 4 months.
There are 3 other peers that have a rating on VOR. Out of the 3 peers that are also analyzing VOR, 0 agree with Matthew's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Matthew
- Carter Gould of "Barclays" Maintained at Buy with Decreased Target to $15 on, Friday, November 11th, 2022
- Swayampakula Ramakanth of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $20 on, Monday, August 15th, 2022
- David Nierengarten of "Wedbush" Initiated at Buy and Held Target at $18 on, Tuesday, July 26th, 2022
